The T cells of the immune system can destroy tumours, but their activation can be inefficient. Vaccines that exploit tumour mutations elicit robust T-cell responses to tumours, with potential clinical benefits. See Letters p.217 & p.222
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer
Cancer Immunology, Immunotherapy Open Access 16 February 2023
-
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
Journal of Experimental & Clinical Cancer Research Open Access 13 September 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
References
Pitt, J. M. et al. Ann. Oncol. 27, 1482–1492 (2016).
Naidoo, J. et al. Ann. Oncol. 26, 2375–2391 (2015).
Castle, J. C. et al. Cancer Res. 72, 1081–1091 (2012).
Gubin, M. M. et al. Nature 515, 577–581 (2014).
Carreno, B. M. et al. Science 348, 803–808 (2015).
Ott, P. et al. Nature 547, 217–221 (2017).
Sahin, U. et al. Nature 547, 222–226 (2017).
van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. Nature Rev. Cancer 16, 219–233 (2016).
Szczepaniak Sloane, R. A. et al. Cancer 123, 2130–2142 (2017).
Kreiter, S. et al. Cancer Res. 70, 9031–9040 (2010).
Hirschhorn-Cymerman, D. et al. J. Exp. Med. 209, 2113–2126 (2012).
Haabeth, O. A. et al. Leukemia 30, 1216–1220 (2016).
Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. & Melief, C. J. Nature 393, 480–483 (1998).
Janssen, E. M. et al. Nature 421, 852–856 (2003).
Alexandrov, L. B. et al. Nature 500, 415–421 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares competing financial interests. See go.nature.com/2sqtds6 for details.
Related links
Rights and permissions
About this article
Cite this article
Melief, C. Precision T-cell therapy targets tumours. Nature 547, 165–167 (2017). https://doi.org/10.1038/nature23093
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature23093
This article is cited by
-
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer
Cancer Immunology, Immunotherapy (2023)
-
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells
Nature Immunology (2021)
-
Liquid dynamic medicine and N-of-1 clinical trials: a change of perspective in oncology research
Journal of Experimental & Clinical Cancer Research (2017)